Our attorneys have filed a mass tort lawsuit on behalf of individuals who took the blood thinner Xarelto (rivaroxaban) and suffered severe bleeding events. Pharmaceutical organizations, including the makers of Xarelto, possess a duty to make sure that their drugs are reasonably protected for use – and failure to do so might be grounds for compensation. Our lawyers are functioning difficult to get those hurt by the drug the compensation they may be entitled to.
While bleeding is a widespread complication related with anticoagulants, it has been alleged that Xarelto is more dangerous than conventional blood thinners because no antidote exists to reverse its blood-thinning effects. This indicates that, within the event of an emergency, patients may possibly be at threat for irreversible bleeding issues, including life-threatening internal and gastrointestinal hemorrhaging.
In case you or a loved 1 suffered a significant bleeding event following taking Xarelto, you might have legal recourse. For much more info, get in touch with us today to have your case reviewed, totally free of charge.
Compensation Possibilities
xarelto-compensation-photoThe plaintiffs in these lawsuits are searching for compensation from Bayer and Janssen for past and future health-related bills, lost wages, pain and suffering and, in cases of death, funeral costs. In addition, they are in search of punitive damages, that are usually awarded to punish the defendant and deter other firms from acting similarly.
Why Are Lawsuits Being Filed?
Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Inc. are facing several Xarelto lawsuits alleging that the drug is hazardous and defective. The plaintiffs claim that, unlike conventional anticoagulants (e.g. warfarin, Coumadin) whose blood-thinning effects can be reversed using vitamin K, there is no antidote available for Xarelto. Because of this, the lawsuits claim, doctors have no effective signifies of stopping Xarelto users from bleeding in the event of an emergency. Plaintiffs within the lawsuits allege serious and fatal injuries, like cerebral hemorrhaging and gastrointestinal bleeds, from use of the drug.
In addition to these risks, lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals are alleging:
The manufacturers of xarelto cases marketed the drug as a superior in the field of anticoagulants despite studies finding higher rates of gastrointestinal (GI tract) bleeding and transfusions in Xarelto users than users of certain competitors.
The makers of the drug continue to market Xarelto as a protected anticoagulant option.
Doctors and medical staff were not properly made aware of methods to stabilize and treat a Xarelto user in the occasion of a bleeding complication.
Users of Xarelto were not adequately warned of the health risks of suffering a fatal bleeding event.
Xarelto is linked to serious bleeding complications, excessive blood loss, intracranial hemorrhaging, eye bleeding (vitreous hemorrhage), stomach bleeding, gastrointestinal bleeding, wound infections from inhibited clotting, and lack of effectiveness in preventing unsafe clotting.
Visit this page for far more information on the alleged health risks of Xarelto.
Multidistrict Litigation Trial Dates Set
The attorneys inside the Complex Litigation Group have filed lawsuits on behalf of injured clients. The claims will proceed through multidistrict litigation (MDL), which currently entails four trials, scheduled for Fall 2016, in which random groups of plaintiffs will be chosen to represent the group.